NeoGenomics (NEO) Scheduled to Post Quarterly Earnings on Tuesday

NeoGenomics (NASDAQ:NEO) is set to issue its quarterly earnings data before the market opens on Tuesday, April 30th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter. NeoGenomics has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, February 20th. The medical research company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.05. NeoGenomics had a negative net margin of 14.87% and a negative return on equity of 4.13%. The business had revenue of $155.55 million for the quarter, compared to the consensus estimate of $152.90 million. On average, analysts expect NeoGenomics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NeoGenomics Stock Performance

Shares of NEO stock opened at $14.14 on Friday. The company’s fifty day simple moving average is $15.04 and its 200-day simple moving average is $15.92. NeoGenomics has a 52 week low of $11.03 and a 52 week high of $21.22. The company has a current ratio of 6.20, a quick ratio of 5.95 and a debt-to-equity ratio of 0.57. The company has a market cap of $1.81 billion, a PE ratio of -20.20 and a beta of 1.10.

Insiders Place Their Bets

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 2,587 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.96, for a total transaction of $38,701.52. Following the sale, the general counsel now directly owns 34,866 shares in the company, valued at approximately $521,595.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. William Blair reissued an “outperform” rating on shares of NeoGenomics in a research note on Wednesday, February 21st. The Goldman Sachs Group raised their price target on shares of NeoGenomics from $17.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. Needham & Company LLC raised their price target on shares of NeoGenomics from $21.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, February 21st. Finally, Piper Sandler raised their price target on shares of NeoGenomics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Monday, February 26th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, NeoGenomics currently has an average rating of “Moderate Buy” and an average target price of $19.50.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.